BodyCoding
Research

GLP-1-based therapies for reduction of heart failure and cardiovascular outcomes: A systematic review and meta-analysis of randomized controlled trials

Researchers conducted a systematic review and meta-analysis of randomized controlled trials to evaluate the effects of GLP-1-based therapies on cardiovascular mortality, heart failure hospitalization, unstable angina hospitalization, nonfatal myocardial infarction, and nonfatal stroke. The analysis included 11 trials with 81,948 participants. Results showed that GLP-1-based therapy significantly reduced cardiovascular mortality, heart failure hospitalization, nonfatal myocardial infarction, and nonfatal stroke. However, no significant benefit was observed for unstable angina hospitalization. Heterogeneity was observed for some outcomes.

What to check after reading

Meta-analysis indicates cardiovascular benefits of GLP-1 therapies, though heterogeneity exists and no significant benefit was seen for unstable angina hospitalization.

Source

PubMed ↗

Calendar dates show when a case was added or scheduled. For event dates, check the original source.